Your SlideShare is downloading. ×
Respiratory disorders therapeutics market to 2017   novel
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Introducing the official SlideShare app

Stunning, full-screen experience for iPhone and Android

Text the download link to your phone

Standard text messaging rates apply

Respiratory disorders therapeutics market to 2017 novel

97
views

Published on

Published in: Health & Medicine, Business

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
97
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Aarkstore.com announces, The Latest market research report is available inits vast collection:Respiratory Disorders Therapeutics Market to 2017 - NovelPipeline Molecules such as VX-770 and pirfenidone May OffsetNegative Effect of Patent Expirieshttp://www.aarkstore.com/reports/Respiratory-Disorders-Therapeutics-Market-to-2017-Novel-Pipeline-Molecules-such-as-VX-770-and-pirfenidone-May-Offset-Negative-Effect-of-Patent-Expiries-155026.htmlYou can also request for sample page of above mention reports onsample@aarkstore.comSummaryCompany Research, the leading business intelligence provider, has released its latestresearch, “Respiratory Disorders Therapeutics Market to 2017 - Novel PipelineMolecules such as VX-770 and pirfenidone May Offset Negative Effect of PatentExpiries”, which provides insights into the global respiratory disorders market andmarket forecast until 2017. The report provides an in-depth analysis of the topseven respiratory disorders indications, which includes asthma, COPD, pulmonary
  • 2. arterial hypertension, idiopathic pulmonary fibrosis, allergic rhinitis, cystic fibrosisand bronchitis. In addition, the report also includes insights into the respiratorydisorders R&D pipeline. Company research analysis estimated that 55% of therevenues are generated by AstraZeneca, GSK, Novartis, Merck, Roche, UCB Inc,Actelion and Takeda. Other companies generate 45% of the revenues in therespiratory disorders therapeutics market. AstraZeneca is the leading company inthe respiratory disorders therapeutics market. The large amount of fragmentationin the market provides significant scope for consolidation through mergers andacquisitions. Strategic through acquisition accounted for 53% of the M&A deals.Scope- The report analyzes market characterization, pipeline analysis and key M&Atrends in the asthma, COPD, pulmonary arterial hypertension, idiopathic pulmonaryfibrosis, allergic rhinitis, cystic fibrosis and bronchitis therapeutics market.- Data and analysis on the global respiratory disorders market in the leadinggeographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.- Annualized market data for the respiratory disorders market from 2002-2010 withforecasts to 2017.Table of Contents :1.1 List of Tables 61.2 List of Figures 102 Respiratory Disorders Therapeutics Market to 2017 - Introduction 132.1 GBI Research Report Guidance 143 Respiratory Disorders Therapeutics Market to 2017 - Market Overview 153.1 Introduction 153.2 Revenue Forecasts for Respiratory Disorders Therapeutics Market 153.2.1 Revenues 153.2.2 Annual Cost of Therapy 203.3 Treatment Usage Patterns 213.4 Drivers and Barriers for Respiratory Disorders Therapeutics Market 233.4.1 Drivers for Respiratory Disorders 233.4.2 Barriers for Respiratory Disorders 24
  • 3. 4 Respiratory Disorders Therapeutics Market to 2017 - Geographical Landscape 254.1 The US 254.1.1 Revenue 254.1.2 Annual Cost of Therapy 264.1.3 Treatment Usage Pattern 274.2 Top Five Countries of Europe 294.2.1 Revenue 294.2.2 Annual Cost of Therapy 324.2.3 Treatment Usage Pattern 334.3 Japan 354.3.1 Revenue 354.3.2 Annual Cost of Therapy 364.3.3 Treatment Usage Pattern 375 Respiratory Disorders Therapeutics Market to 2017 - Therapeutic Landscape 395.1 Asthma 395.1.1 Introduction 395.1.2 Revenue 395.1.3 Annual Cost of Therapy 445.1.4 Treatment Usage Patterns 455.1.5 Treatment Flow Algorithm 475.1.6 Drivers and Barriers for Asthma 485.2 COPD 505.2.1 Introduction 50List of FiguresList of Tables are also include.For more Discounted Reports Plz follow The link:Spinal Surgery Devices Market - Global Pipeline Analysis, Competitive Landscapeand Market Forecasts to 2017 - Motion Preserving Spinal Non-Fusion Procedures to
  • 4. Drive Long Term GrowthOphthalmic Devices Market to 2017 - Glaucoma and Cataract Surgery Devices,Minimally Invasive Procedures in Ophthalmic Surgery to Drive the OphthalmicSurgery MarketOncology Therapeutics Market to 2017 - High Unmet Need in the Management andTreatment of Metastatic Cancers to Drive Drug DevelopmentSearch More Reports Related to This Category :Pharmaceuticals and Healthcarehttp://www.aarkstore.com/market-sector-reports/Pharmaceuticals-&-Healthcare-7.htmlEndpoints - Clinical Trials in Respiratory Diseases - Pulmonary Function Tests,Biomarkers and Quality of Life Questionnaires All Play Prominent RolesRespiratory Disorders Therapeutics Market to 2017 - Novel Pipeline Molecules suchas VX-770 and pirfenidone May Offset Negative Effect of Patent ExpiriesFor More details Plz do contact :Aarkstore EnterpriseLavanyaPhone:08149852585Email: enquiry@aarkstore.com